Denosumab 60 mg vs 120 mg: What the Prolia and Xgeva Labels and Trials Report
Denosumab 60 mg vs 120 mg is a comparison hospital pharmacies run into often, because the same medicine is stocked in two very different forms under two different brand names. The 60 mg product (sold as Prolia) and the 120 mg product (sold as Xgeva) contain the same antibody, yet their approved uses, labelled schedules […]
Epinephrine Auto-Injectors in India: What the EpiPen Label and Anaphylaxis Guidance Report
Epinephrine (adrenaline) auto-injectors such as EpiPen and EpiPen Jr are single-dose, pre-filled devices that deliver a fixed dose of epinephrine into the outer thigh. Several recent items bear on how they are discussed: the US prescribing information for EpiPen and EpiPen Jr was revised in March 2026; an international expert panel published consensus recommendations on […]
Fetroja (Cefiderocol) in India: What Published Data Say About This Siderophore Cephalosporin
Cefiderocol, sold as Fetroja, is a cephalosporin antibiotic designed to enter Gram-negative bacteria through their own iron-uptake systems. Three recent developments make it worth a fresh look: the Infectious Diseases Society of America (IDSA) published a new edition of its resistant Gram-negative guidance on 30 July 2026; the US prescribing information for Fetroja was revised […]
2026 Cholesterol Guideline and VESALIUS-CV: What the New Data Say About PCSK9-Pathway Therapy in India
1. Why Cholesterol Guidance Is in the News Again Over the past twelve months, cardiology has produced an unusually dense run of lipid-related publications. A new US dyslipidemia guideline replaced the 2018 cholesterol guideline, a large outcomes trial of a PCSK9 antibody in patients with no prior heart attack or stroke was published, and the […]
Copellor (Ixekizumab) India — What Hospitals and Dermatologists Need to Know
1. What Is Copellor (Ixekizumab)? Copellor® is the brand name for Ixekizumab, a humanised anti-interleukin-17A (anti-IL-17A) IgG4 monoclonal antibody manufactured by Eli Lilly and Company India Pvt Ltd and approved by the Drugs Controller General of India (DCGI). It is available as an 80mg/mL subcutaneous injection in a pre-filled syringe or auto-injector. Ixekizumab works by […]
Endoprost (Alprostadil) India — What Hospitals Need to Know
For hospital pharmacists, neonatologists, vascular surgeons, and urologists sourcing critical-care injectables in India, Endoprost (Alprostadil) is one of the most clinically important — and procurement-sensitive — medicines on any formulary. This guide covers what hospital procurement teams across India need to know about Alprostadil: what it is, which clinical departments depend on it, how it […]
Imfinzi (Durvalumab) in India 2026 — What Hospitals and Oncology Centres Need to Know
Imfinzi is one of the most searched oncology medicines on akpharma.in — generating over 1,400 impressions per month at position 6 on Google, with a click-through rate that suggests the page is being found but not telling visitors enough to bring them through. This article fills that gap. Whether you are a hospital pharmacist managing […]
Checkpoint Inhibitors in India 2026 — What Has Changed and What Hospitals Need to Prepare For
Five years ago, checkpoint inhibitor immunotherapy was a treatment category that most Indian oncology centres had limited access to — expensive, largely imported, and available through relatively few distribution channels. In 2026, the landscape looks fundamentally different. Multiple checkpoint inhibitors are now available in India across different mechanisms, different indications, and increasingly different price points. […]
The Difference Between a Biosimilar and a Generic — What Hospital Pharmacists Need to Know
In hospital pharmacy conversations across India, two words get used interchangeably more often than they should: generic and biosimilar. Both refer to non-originator versions of existing medicines. Both are generally less expensive than the originator product. And both require regulatory approval before they can be sold. But beyond those surface similarities, the two are fundamentally […]
Dupixent in India 2026 — What Patients and Hospitals Need to Know
Dupixent is one of the most searched medicine names on akpharma.in — consistently generating nearly 2,000 impressions per month and sitting at position 5 on Google for dupixent-related queries. The searches are coming from two very different groups of people: patients and families who have been prescribed Dupixent and want to understand what it is, […]
